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ABSTRACT
Nucleoporin 153 (Nup153), key regulator of nuclear import/export, has been 
recently associated to oncogenic properties in pancreatic and breast tumour cells 
modulating either cell motility and migration or gene expression by chromatin 
association.
In the present work, we have characterized the role of Nup153 in a cellular 
model of prostate cancer (PCa). The analysis of several immortalized cell lines derived 
from freshly explants of prostate cancer specimens showed that Nup153 protein 
was higher and present in multimeric complexes with eNOS and ERβ as compared to 
normal/hyperplastic prostate epithelial cells. This phenomenon was enhanced in the 
presence of 17β-estradiol (E2, 10-7M). Further experiments revealed that eNOS and 
ERβ were present in a DNA binding complexes associated with Nup153 promoter as 
demonstrated by ChIPs. Notably, after Nup153 depletion (siNup153), a reduction of 
migration capacity and colony formation in primary tumor-derived and metastatic 
PCa cells was observed. In addition, eNOS and ERβ nuclear localization was lost upon 
siNup153 regardless of E2 treatment, suggesting that Nup153 is a key regulator of 
prostate cancer cell function and of the nuclear translocation of these proteins in 
response to hormone stimulus. Taken altogether our findings indicate that in PCa 
cells: i. the expression and function of Nup153 is modulated by estrogen signaling; 
ii. Nup153 contributes to cell migration and proliferation; iii. Nup153 regulates the 
nuclear translocation of eNOS and ERβ by forming a multimeric complex. Our findings 
unveil Nup153 as a novel component of the estrogen-dependent multimeric complex, 
thus representing a potential therapeutic candidate in prostate cancer.
INTRODUCTION
Nucleoporins (NUPs) are components of the nuclear 
pore complex which spans the nuclear envelope and allows 
the transport between the cytoplasm and the nucleus. 
Nucleoporin 153 (Nup153) is placed at the inner part of 
the nuclear envelope forming the nuclear basket with other 
peripheral NUPs, where it interacts with the nuclear matrix. 
Interestingly, several NUPs are capable, upon still unknown 
signals, to move to nucleoplasm and interact with chromatin, 
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thus contributing not only to nuclear import/export but also 
to chromatin organization and gene expression regulation. 
Specifically, it has been recently demonstrated that Nup153 
represents a new class of global chromatin-binding proteins 
regulating the spatial organization of chromosomes associating 
at very high density with transcriptionally active regions 
[1, 2]. NUPs, including Nup153, appear to be implicated 
in a large number of disorders, such as cardiomyopathy 
associated to muscular dystrophy [2], autoimmune disease 
and cancer [3, 4]. In this regard, several reports established 
that NUPs regulate cancer through different mechanisms 
based either on the import of DNA repair proteins [5] or gene 
regulation [3]. Increased expression of Nup153 due to a 6p22 
genomic translocation was detected in urothelial carcinoma 
and retinoblastoma [6, 7]. Moreover, in a screening for 
genes, Nup153 was found amplified in the pancreatic cell 
line PL5 [8]. This study suggested an oncogenic function 
for Nup153 by modulating the TGF-β signalling pathway. 
Furthermore, Nup153 is important for tumor cell migration 
and proliferation [9] which are essential features of metastatic 
cancers. Of note, Nup153 knockdown was responsible for the 
alteration of nuclear lamin A in these cancer cells. Indeed, 
the function of nuclear envelope and nuclear matrix are 
intimately connected and linked to chromatin structure and 
integrity and are often altered in cancer cells.
Previous works from others and our group identified 
a molecular mechanism that sustains the aggressive 
phenotype of prostate cancer (PCa) [10, 11]. The endothelial 
nitric oxide (NO) synthase (eNOS) in fact, plays a key role 
in prostate tumor maintenance and progression by forming 
complexes with Estrogen Receptors (ERs) [12–14] which 
exert an epigenetic control of gene expression. Importantly, 
the localization of eNOS-containing nuclear complexes, 
as assessed by ChIP-Seq, shows a specific pattern in 
response to 17β-estradiol (E2) treatment contributing to the 
acquisition of a pathological gene expression signature. 
Overall, these findings are in agreement with the concept 
that NO has a broad negative effects on cancer, sustaining 
cell malignant transformation, cancer progression and the 
metastatic cascade ([15] and references therein).
Here we report about the new role of Nup153 in a 
hormone-driven activation cascade, involving eNOS and NO 
production, which contributes to a transcriptional program 
associated with prostate cancer. In fact, hormone-dependent 
eNOS activation enhances Nup153 expression which is 
followed by nuclear import of eNOS/ERβ by the formation of 
eNOS/ERβ/Nup153 complexes. Our results suggest Nup153 
as potential therapeutic target in prostate cancer.
RESULTS
Nup153 regulates cell migration and colony 
formation in prostate cancer cells
To investigate Nup153 potential contribution to 
the biology of prostate cancer two cellular models were 
adopted: human immortalized cell lines derived from 
freshly explanted prostate tumors obtained from patients 
with diagnosis of clinically localized disease and selected 
for the absence of hormonal neoadjuvant treatment before 
surgery [16] and the metastatic prostate cancer cell line 
LNCaP. We first evaluated whether Nup153 silencing by 
siRNA could affect migration and clonogenic ability of 
prostate cancer cells.
A significant reduction of migration capacity as well 
proliferation was found in primary tumor-derived (C27IM, 
not shown) and metastatic (LNCaP) PCa cells undergoing 
to Nup153 downregulation as shown by scratch test and 
colony formation assay (Figure 1A-1B). Nup153 silencing 
progressively reduced cell metabolic activity (Figure 1C), 
in agreement with its essential role in cell viability and 
control of cell cycle [17–19].
When we analysed Nup153 expression by confocal 
microscopy we found that in the unstimulated conditions 
Nup153 protein level was higher in PCa cells (C38IM 
and C27IM) as compared to Benign Prostate Hyperplasia 
(BPH) cells (C17IM) (Figure 1D, upper panels). Nup153 
knockdown has been previously linked to alteration of the 
nuclear lamin A in breast cancer cells [9]. Interestingly, 
in PCa cells (C38IM and C27IM), that show increased 
level of Nup153, the organization of nuclear lamin A, was 
also altered and the nuclei showed irregular shapes with 
membrane invaginations and multiple lobes (Figure 1D, 
lower panels and right graph).
Hormone-dependent eNOS activation regulates 
Nup153 expression in PCa cells
Our PCa cell lines show a particular aggressive 
phenotype that we found to be mainly dependent on a 
basal higher estrogenic responsiveness that determines in 
turns eNOS and ERβ nuclear accumulation and complexes 
formation, which drive a pathological gene expression 
[13, 14]. Thus, we reasoned that the higher basal level 
of Nup153 in PCa cells compared to BPH could be a 
consequence of a potential hormone-responsiveness 
of Nup153, mediated by eNOS activation, in prostate 
microenvironment [12–14, 20–24]. In order to understand 
the contribution of estrogenic signalling in this pathway, 
PCa cells were cultured for 72 hours in hormone-deprived 
serum and then treated or not with 17β-estradiol. In the 
above conditions, we analysed the regulatory region at 5’ 
Nup153 gene on our ChIP-Seq database [12]. Intriguingly 
this analysis revealed a hormone-dependent localization of 
eNOS-DNA association peaks along Nup153 extragenic/
intronic regions, strongly supporting the hypothesis of 
an estrogen-dependent regulation of Nup153 (Figure 
2A). By an independent set of traditional ChIP in C27IM 
cells we validated the hormone-induced eNOS binding 
downstream to TSS within Nup153 genomic region, 
confirming that Nup153 is a transcriptional target of 
eNOS. In addition, an estrogen-dependent recruitment of 
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ERβ was also found onto Nup153 promoter, suggesting 
the formation of a combinatorial chromatin complex 
eNOS/ERβ along that genomic region (Figure 2B). To 
further corroborate our finding a second antibody to ERβ, 
the CWK-F12 [25, 26], also suitable for ChIP assays, was 
used, confirming recruitment of ERβ in basal as well in 
the estrogen-stimulated condition onto Nup153 promoter 
(Supplementary Figure 1).
We next investigated the responsiveness to E2 of 
Nup153 in terms of RNA and protein expression. To address 
Figure 1: Nup153 depletion in PCa cells regulates migration and colony formation. (A) Representative phase contrast images 
(Bright field) of a scratch test in a time course of 24h (left panel) and its quantification (right panel, down), expressed as percentage of 
remaining gap, in Nup153 silenced (siNUP153 oligos mix; 60nM), scramble control and mock transfected LNCaP cells. The wound was 
made 48h after transfection. Nup153 protein level in the above conditions is shown in the western blot (right panel, up). (B) Left panel: 
Representative digital image showing colonies produced by PCa (C27IM) cells after plating 150 cells. Cells were transfected in the same 
experimental conditions of scratch test and, after eight days, were fixed and stained with hematoxilin. In the right panel, the number 
of colonies for each condition is shown. Data expressed as mean +/-SEM of 3 independent experiments. * p< 0.05 vs mock. (C) Cell 
Viability in a time course of 72h in the same experimental conditions as described for scratch test. Data are expressed as mean +/-SEM of 3 
independent experiments in triplicate, corrected to fluorescence background. $ p< 0.05 vs scramble. (D) Confocal analysis of PCa (C27IM 
and C38IM) and Benign Prostatic Hyperplasia (BPH, C17IM) cells stained with antibodies to Nup153 ([QE5]; red) or Lamin A (green). 
Scale bar: 20 μm (Nup153 and Lamin A). The graph shows the percentage of nuclei bearing invaginations (right panel). * p< 0.05 vs BPH. 
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this point, quantitative RealTime PCR (qRT-PCR), western 
blot, and confocal microscopy were performed in PCa 
and BPH cells cultured for 72 hours in hormone-deprived 
serum and then treated with 17β-estradiol (E2;10
-7M) for 
1, 3, 6 and 24 hours. In BPH cells Nup153 mRNA level 
was weakly affected by E2 treatment exhibiting a similar 
extent at each time course considered (Figure 2C), while 
an induction of Nup153 was observed in PCa cells. Similar 
results were obtained for Nup153 protein expression that 
was unaffected in BPH and induced in PCa cells by E2 
treatment (Figure 2D). Hormone-driven Nup153 protein 
increase was prevented in the presence of 7-nitroindazole 
(7N) an inhibitor of the NOS function as demonstrated by 
confocal and western blot analyses (Figure 2E–2F). The 
key role of eNOS in regulation of Nup153 expression was 
confirmed using W7, an inhibitor of Calmodulin function, 
which is upstream of the eNOS activation, determining 
Nup153 downregulation in PCa cells (Figure 2G).
Nup153 is part of a multimeric complex induced 
upon estrogen stimulation
We previously demonstrated that eNOS nuclear 
import, followed by the formation of transcriptional 
complexes with ERβ, occurs in PCa cells under basal 
condition and is enhanced under estrogen stimulus [13]. 
To understand whether and how Nup153 may take part 
of this activation pathway we investigated the possible 
formation of protein complexes potentially important 
for both eNOS nuclear translocation and its activation 
for transcriptional activity. We analysed the cells either 
in basal condition or after estrogenic deprivation (NT) 
followed or not by E2 treatment for 3h and 45min and/
or 24h (E2). Confocal microscopy analysis revealed co-
localization of eNOS and Nup153 predominantly in PCa 
cells in basal condition (Figure 3A). Quantification of 
double-labelled areas in BPH or PCa cells was 2% vs. 
38%, respectively (not shown). Co-IP for eNOS (Figure 
3B) confirmed an interaction between Nup153 and eNOS 
that was stronger in tumor (PCa, C38IM and C27IM) as 
compared to BPH (C17IM) cells used as normal control.
Additional Co-IP experiments were performed in PCa 
cells (C27IM), endogenously expressing ERβ, before and 
after E2 stimulation. Either immunoprecipitation for ERβ 
and Nup153, revealed that hormone treatment induced the 
formation of a trimeric complex containing eNOS, ERβ 
and Nup153 (Figure 3C). To reinforce our finding we used 
an alternative antibody proved highly specific for ERβ and 
an additional cell line, HeLa, known to be ER-negative. 
We performed a Co-IP for Nup153 (Figure 3D) in HeLa 
transfected with human ERβ full-length in basal or upon E2 
treatment. Results confirmed a specific interaction among 
Nup153, ERβ and eNOS in HeLa cells also using this 
different antibody for ERβ.
Nup153 association with histone acetylases 
(HATs) regulates their activity in cardiomyocytes 
bearing dystrophin mutation [2]. Other reports also have 
shown that epigenetic enzymes function and chromatin 
association are regulated by nucleoporins [27]. Thus, 
we first investigated by Co-IP the potential Nup153 
interaction with the HAT member p300 and found that E2 
treatment strongly enhanced their association in PCa cells 
compared to un-stimulated and estrogen-deprived cancer 
cells (Figure 3E). We found also, that E2 was capable of 
modulating the acetylase activity specifically associated 
with Nup153 (Figure 3F) suggesting the formation of 
a transcriptionally competent complex upon estrogen 
stimulation.
To explore further the role of Nup153 in the E2 
signalling we analysed the expression of VEGF Type2 
Receptor (VEGFR2/KDR), an E2-target gene, after 
Nup153 silencing and under hormone stimulation. 
Nup153 depletion virtually abrogated VEGFR2/KDR E2-
responsiveness thus confirming Nup153 transcriptional 
role in this context (Figure 3G).
Nup153 regulates eNOS and ERβ nuclear import 
in a hormone-dependent manner
The evidence of the nuclear interaction between 
eNOS and ERβ with Nup153 prompted us to investigate 
whether Nup153 had a role in nuclear transport of these 
proteins. By confocal microscopy, we analysed eNOS and 
ERβ nuclear shuttling, upon E2 treatment, in PCa cells that 
were silenced for Nup153 or treated with scramble oligo 
as control.
Nup153 expression was highly induced upon 
E2 treatment at the two time points (3h45min; 24h) 
and in parallel eNOS and ERβ were imported into the 
nucleus (Figure 4A–4B). However, Nup153 silencing 
strongly reduced the presence in the nucleus of eNOS 
and ERβ both in NT and in E2 treated cells (Figure 
4A–4B). Similar results were obtained in an additional 
immunofluorescence experiment performed with the 
validated antibody to ERβ (CWK-F12, DHSB) and 
a rabbit antibody to Nup153 ([H-161], Santa Cruz) 
(Supplementary Figure 2).
To assess the specificity of Nup153-dependent eNOS 
and ERβ nuclear import we evaluated the effects of Nup153 
depletion on nucleo-cytoplasmic protein trafficking, with 
particular attention to the localization of the exogenous 
Green Fluorescent Protein (GFP), in p-GFP transfected 
cells, and the endogenous Histone deacetylase 2 (HDAC2) 
proteins. No modification of GFP and HDAC2 localization 
was indeed observed upon siNup153, thus indicating that 
inhibition of eNOS and ERβ nuclear translocation after 
Nup153 depletion is specific (Figure 4C–4D).
DISCUSSION
Many studies demonstrated a link between aberrant 
nuclear shape and tumorigenesis. Indeed, components 
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of the nuclear envelope have been implicated in the 
regulation of several cell functions affected during 
cancer initiation and progression, such as proliferation, 
migration and DNA repair. In this context we have found 
that the nuclear pore component Nup153 plays a key 
role in the aberrant estrogen response of prostate cancer, 
Figure 2: eNOS binds Nup153 promoter and regulates its expression in an estrogen-dependent manner. (A) Integrated 
Genome Viewer (IGV 2.3) screenshot showing peaks of eNOS identified by ChIP–Seq at the genomic regions encoding Nup153 in PCa 
cells (C27IM) in the absence (NT) or presence of 17β-estradiol (E2, 10
-7M, 45min). Region amplified in panel B is indicated with a red 
circle. (B) Recruitment of eNOS and ERβ on the promoter region of Nup153 by ChIPs in the presence or absence of E2 (45 min) in C27IM 
cells. The immunoprecipitations were performed using anti-eNOS (Type III, BD), anti-ERβ (L-20) or no antibody (NoAb) as a negative 
control. Values are represented as fold of induction (+/-E2) and as mean +/-SEM of 3 independent experiments. 
*p<0.05 E2 vs NT. (C) 
Nup153 mRNA levels quantified by qRT-PCR in PCa and BPH cells in basal condition (NT) and after E2 in a time course of 1, 3, 6 or 24 
hours. The results are plotted as fold induction vs NT +/-SEM of 3 independent experiments.*p<0.05 E2 vs NT. (D) Nup153 protein levels 
were analysed by western blot in PCa and BPH cells in a time course of 1, 6 or 24 hours. Numbers represent optical density analysis of 
bands normalized to loading control. Data are mean +/-SEM of 3 and 4 independent experiments for BPH and PCa, respectively. *p< 0.05 vs 
NT. (E) Confocal analysis of Nup153 ([QE5]; red) in PCa cells untreated (NT) or treated with E2 (10-7M) and/or 7N (0.5 mM) for 6 hours. 
Nuclei were counterstained with DAPI (blue) and merged with the Nup153 signal (red). Scale bar 25μm. (F-G) Protein level analysis of 
Nup153 before and after E2 (10
-7M, 6h) alone or in combination with 7N (0.5 mM, 6h) (F) and upon W7 (G) treatment (25 μM and 50μM, 
overnight). Right Panel: Representative western blot of Nup153. Fibrillarin served as loading control. Left Panel: Numbers represent 
optical density analysis of bands normalized to loading control. Data are mean +/-SEM of 3 for W7 and 4 for 7N independent experiments. 
*p< 0.05 vs NT; $ p< 0.05 vs E2.
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Figure 3: Nup153 forms complexes with eNOS, ERβ and p300.  (A) Confocal analysis of Prostate Cancer (PCa, C27IM) and 
Benign Prostatic Hyperplasia (BPH, C17IM) cells stained with antibodies to Nup153 ([QE5]; red) or eNOS (Type III; green). Scale bar: 
20μm (Nup153, eNOS and MERGE; zoomed area is showed). (B) Analysis of Nup153 interaction with eNOS by Co-Immunoprecipitation 
in PCa and BPH cells in basal condition. Immunoprecipitation with IgG served as negative control. (C) Analysis of Nup153 interaction 
with eNOS and ERβ by Co-Immunoprecipitation in PCa cells in basal condition or upon E2 treatment (10
-7M, 24h). PCa cells were 
immunoprecipitated with Nup153 Antibody ([7AB], Abcam) or with ERβ (GeneTex, #110607). Immunoprecipitation with IgG served 
as negative control. Membranes were blotted with specific antibodies to Nup153 ([Q5], Abcam), ERβ (GeneTex, #110607) and eNOS 
(Type III, BD). H1 served as control. 4μg of transfected HeLa with human ERβ short isoform (485aa) were used as positive control 
for Estrogen Receptor. Total proteins were resolved by SDS-PAGE using a 10% Invitrogen precast gel (NuPage and MES buffer). (D) 
Analysis of Nup153 interaction with eNOS and ERβ by Co-Immunoprecipitation in HeLa cells transfected with empty vector (PSG5) or 
with human ERβ full-length (ERβ 530aa), before and after E2 treatment (10
-7M, 24h). HeLa cells were immunoprecipitated with Nup153 
Antibody ([7AB], Abcam). Immunoprecipitation with IgG served as negative control. Membranes were blotted with specific antibodies 
to Nup153 ([QE5], Abcam), ERβ (CWK-F12, DHSB) and eNOS (Type III, BD). Hsp90 served as control. Total cell lysates (15μg) from 
HeLa transfected with human ERβ 530aa isoform were used as positive control for Estrogen Receptor. * indicates a lower exposure for 
INPUT and positive control, respectively. Total proteins were resolved by SDS-PAGE using a 3-8% Invitrogen precast gel (NuPage and 
TA buffer). (E) Analysis of Nup153 interaction with Histone Acetyl Transferase p300 by co-immunoprecipitation in PCa cells in basal 
condition or upon E2 treatment (10
-7M, 24h). Immunoprecipitation with IgG was used as negative control. Fibrillarin served as loading 
control. * indicates a lower exposure for INPUT. Densitometric analysis showing, in the right panel, the interaction of Nup153 with p300 in 
E2 treated samples versus NT, normalized to input loading control and expressed as fold change. Data are mean +/-SEM of 3 independent 
experiments. *p< 0.05 vs NT. (F) Evaluation of HAT activity specifically associated with Nup153 in total extracts of PCa cells cultured in 
absence or in presence of E2 (10
-7M, 24h) and subjected to immunoprecipitation with anti-Nup153 antibody ([7AB], Abcam) or normal IgG 
immunoglobulin as negative control. Data are expressed as mean +/-SEM of 3 independent experiments. A.U. Arbitrary Unit *p<0.05 E2 
vs NT. (G) Effect of Nup153 depletion on estrogen response gene. VEGF Type2 Receptor (KDR) mRNA levels quantified by qRT-PCR in 
PCa cells before (scramble) and after Nup153 depletion (siNUP153 oligos mix, 60 nM), untreated or treated with E2 (10
-7M, 6 and/or 24 
hours). The results are plotted as Fold change vs NT, +/-SEM of 5 independent experiments.*p<0.05 E2 vs NT.
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promoting the nuclear import of important determinants 
of transcription such as ERβ and eNOS which have been 
demonstrated to cooperate in driving the pathological gene 
signature.
Moreover, under estrogen induction, these effectors 
bind to Nup153 promoter region, increasing its protein 
level and consequently the nuclear import of eNOS/ERβ 
thus amplifying the effects on gene expression alteration 
Figure 4: Nup153 controls eNOS and ERβ nuclear translocation. (A-B) Representative confocal microscopy images of 
eNOS (A) or ERβ (B) nuclear localization (green) in PCa cells before and after Nup153 depletion, untreated or treated with E2 (10
-7M, 
3h45min and/or 24 hours). Cells silenced for Nup153 (oligos mix, 60nM) or treated with scramble control oligo were analysed at 48h 
post-transfection. T3 treatment (10
-7M, 3h45min) served as control of ERβ estrogen response specificity. Nuclei were counterstained with 
DAPI (blue) and merged with the Nup153 ([QE5], Abcam; red) and eNOS (Type III, BD; green) or ERβ (Genetex #110607; green) signals. 
Efficiency of Nup153 interference is assessed also by western blot (right upper panel A). (C) Representative confocal microscopy images 
of GFP localization in PCa-GFP transfected cells before and after Nup153 depletion. Nuclei were counterstained with DAPI and merged 
with the two protein signals (GFP in green and Nup153 [QE5] in red). Scale bar 50 μm. (D) Representative confocal microscopy images of 
HDAC2 localization (green) in PCa cells before and after Nup153 depletion. Nuclei were counterstained with DAPI and merged with the 
HDAC2 signal (green). Scale bar 50 μm.
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and contributing to tumor aggressiveness and the negative 
prognosis for PCa.
The metastatic form of prostate cancer, in fact, is 
generally refractory to therapy and leads rapidly to death. 
Although the mechanistic control of prostate cancer cell 
metastasis is still poorly characterized, it is recognized as 
a multi-step process in which the epithelial-mesenchymal 
transition and the acquisition of enhanced cell motility 
largely contribute to the acquisition of the metastatic 
phenotype.
Our results showing that Nup153 positively 
regulates cell migration and is associated with aberrant 
nuclear structure in PCa is in line with previous findings 
describing the role of this nucleoporin in nuclear shaping 
and cell motility in other cancers [9].
Nucleoskeleton and cytoskeleton are intimately 
connected through the LINC complex [28] thus changes 
in nuclear structural proteins such as Nup153 and 
Lamins, may directly affect cell migration increasing 
the nuclear plasticity necessary for cell deformation 
during intra-extravasation process that characterizes 
metastatic cells [3]. Another important finding of 
our work regards the positive effect of Nup153 on 
the clonogenic capacity of prostate cancer cells thus 
suggesting that targeting this protein could represent 
a possible therapeutic strategy to counteract tumor 
growth. In fact, NUPs are important regulators of cell 
cycle either by taking part in the assembly-disassembly 
process during mitosis or by export of cell cycle 
inhibitors [29].
In the present study, we found that Nup153 is 
overexpressed in primary and metastatic PCa tumor cells as 
compared to benign lesions. Chromatin immunoprecipitation 
analysis suggests that a complex encompassing eNOS and 
ERβ is present on Nup153 promoter region and may then 
regulate its transcription as previously reported for other 
genes belonging to a prognostic signature including the 
telomerase catalytic subunit [13].
In prostate cancer the estrogen responsiveness, 
high levels of ERβ expression [30] associated with 
nuclear accumulation of eNOS [13] may represent a 
negative prognostic condition. Although the signal 
triggering Nup153 expression is still unclear we observed 
that Nup153 expression was induced by estrogens and 
associated with the estrogen property to upregulate the 
intracellular synthesis of nitric oxide (NO). Inhibitors 
affecting NO synthesis or eNOS activation pathway, in 
fact, abrogated the estrogen-dependent Nup153 protein 
increase. This observation is of particular interest 
indicating that both estrogens and NO may cooperate 
and contribute to aggressiveness in prostate cancer [13] 
through Nup153 upregulation.
Prior work described that Nup153 is involved 
in epigenetic processes aimed at controlling nuclear 
trafficking and gene expression [31]. Intriguingly, 
Nup153 has be found associated with chromatin in 
different cellular contexts possibly facilitating expression 
of a number of target genes via microRNAs and small 
interfering RNAs [1, 32]. In this light, the association of 
Nup153 with both ERβ and eNOS in a trimeric complex 
not only is required for nuclear co-translocation of these 
proteins, but also could function as epigenetically active 
scaffold allowing their activity.
The association of Nup153 with other epigenetically 
active components has been previously reported in 
different conditions. Specifically, nucleoporins association 
Figure 5: Cartoon depicting the proposed role for Nup153 as regulator of eNOS and ERβ nuclear translocation and as 
scaffold for p300.  Specifically, Nup153 binds eNOS and ERβ and drives their nuclear translocation. Once in the nucleoplasm Nup153 
interacts with p300. Estrogen signaling affects Nup153 function by favouring its association with eNOS, ERβ and p300 and by increasing 
the acetylase activity specifically associated with Nup153.
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with HDACs has been shown important for their proper 
chromatin localization and gene regulation [27, 33, 34]. 
Prior studies, however, indicated that Nup153 could be 
acetylated in the heart of dystrophic mice. In this context, 
it has been found associated with lysine acetylases 
including p300 and PCAF [2]. These epigenetic enzymes 
function as transcription co-activators facilitating the 
expression of genes present in the chromatin region to 
which they are associated. Remarkably, lysine acetylases 
are always present as cofactors in nuclear hormone 
receptor complexes including those in which ERβ is 
present [35]. In our study, it also emerged that p300 
was associated with Nup153 in prostate cancer cells. 
This experimental evidence together with the specific 
Nup153-associated histone acetylase activity significantly 
incremented in the presence of estradiol is suggestive of 
a functional regulatory loop determining an estrogen-
dependent Nup153 protein complex formation (see 
cartoon in Figure 5). In conclusion, the present report 
highlights the role of the nuclear envelope environment 
as a new player in prostate cancer cell biology. In 
response to estrogens and nitric oxide, Nup153 in 
fact, regulates ERβ and eNOS function through a 
coordinated nuclear import and providing an epigenetic 
scaffold for complex formation and appropriate release 
of the transcriptionally competent complexes in the 
nucleoplasm. The pathological gene expression that is 
estrogen-dependent in PCa is a major determinant of bad 
prognosis and of refractory and metastatic tumors. In this 
light, although further studies are required, our findings 
may suggest that, in addition to standard interventions, 
targeting Nup153 could be a potential new strategy. In 
fact, Nup153 depletion or inactivation could block the 
pathological estrogen signaling that sustains the aberrant 
gene expression in prostate cancer cells thus helping to 
normalize their epigenetic profile, to reduce proliferation 
and migration with important effects on their aggressive 
phenotype and cancer recurrence. This concept is 
indeed substantiated by our finding of abrogation of the 
VEGFR2/KDR estrogen responsiveness upon siNup153, 
given the relevance of the VEGF-VEGFR2 signaling in 
tumor-associated angiogenesis. Thus, in conclusion, the 
multiple roles played by Nup153 in prostate cancer cells 
makes it a potential powerful target to counteract tumor 
aggressiveness.
MATERIALS AND METHODS
Antibodies
The following antibodies were used: anti-
ERβ[L-20] (#sc-6822), anti-p300 [C-20] (#292438), 
anti-Nup153[H161] (#sc-292438) from Santa Cruz 
Biotechnology, Dallas TX, USA; anti-ERβ from GeneTex 
(#110607), Irvine, CA, USA and CWK-F12 from DSHB, 
Iowa City, IA, USA; anti-eNOS Type III (#610299) from 
BD Biosciences, Franklin Lakes, NJ, USA; anti-Nup153 
[QE5] (#Ab24700) for WB and confocal microscopy, and 
[7A8] (#Ab93310) for Co-IP from Abcam; anti-Fibrillarin 
[38F3] from Pierce (#MA3-16771); anti-Lamin A [131C3] 
(#Ab8984) from Abcam; anti-tubulin from Immunological 
Science (#MAB-10285); anti-HSP90 (#SPC-104C)
from StressMarq Biosciences Inc; anti-mouse FITC 
(#715095150) and anti-rabbit TRITC (#711025152) from 
Jackson Immunological Research.
Cell culture and treatments
PCa (C27IM, C11IM and C38IM), LNCaP and 
HeLa cell cultures and treatments were as in [12–14, 
36]. All media were supplemented with 10% fetal 
bovine serum, 2 mM glutamine, 100 ug/ml penicillin and 
streptomycin. At least 72 h before experimental use, cells 
were switched to a medium with hormone-deprived serum 
and treated with 17β-estradiol (E2), triiodothyronine (T3), 
N-(6-Aminohexyl)-5-chloro-1-naphthalenesulfonamide 
hydrochloride (W7) or 7-nitroindazole (7N), for the 
concentrations and the times indicated in the figure 
legends.
Scratch test
Scratch assay was performed as described in [37]. 
Briefly, cells were transfected and cultured to confluence. 
The monolayer was scraped with a p200 pipet tip in a 
straight line to create a “scratch”. Images were obtained 
by using a phase-contrast microscope (AXIO microscope 
with AxioCam ERc5s, Zeiss- objective 10X) in a time 
course of 0, 6 and 24 hours, distance between edges was 
measured by the phase contrast microscopy and analyzed 
by ZEN imaging software (Zeiss). Data were represented 
as percentage of residual gap.
Colony formation assay
Colony formation assay was performed as described 
previously [38]. Briefly, about 2×102 cells were plated 
into a 6-well culture. After incubation at 37°C for 8 days, 
the cells were washed twice with PBS, fixed in methanol 
and stained with Hematoxylin. The number of colonies 
were counted under microscope. Each sample was run in 
triplicate.
Cell viability assay
Cell Viability Assay was performed according to 
manufacturer’s instructions of The CellTiter-Blue Cell 
Viability Assay (Promega). Briefly, about 2×103 cells 
untreated (mock) and transfected with scramble oligo 
or siNup153 oligos mix (60nM) in Reverse mode were 
added into a 96-well culture plate with three replicates for 
each group. The cells were incubated for 24, 48 and 72 h. 
Before the test, cells were washed (with PBS, three times) 
Oncotarget27994www.oncotarget.com
and fresh medium (100 μL) containing the CellTiter-
Blue (20 μL) was added. The plate was incubated for 
1-4 h, protected from light at 37°C with 5% CO2, before 
the measurement of the fluorescent signal. Background 
fluorescence was corrected by including control wells on 
each plate/time tested (24h, 48h and 72h) to measure the 
fluorescence from serum-supplemented culture medium in 
the absence of cells.
HAT activity
Measurement of the lysine acetylase (HAT) activity 
was analyzed as previously described [2, 39]. Briefly, 
Nup153-associated HAT activity was evaluated after 
immunoprecipitation using 400 μg of protein extract. 
Normal IgG served as negative control. 40μg of protein 
extract was used to evaluate total HAT (BioVision) activity 
following manufacturer’s instructions.
Confocal microscopy
Confocal analysis was performed as previously 
described [2, 12–14].
Related to Supplementary Figure 2 the cells were 
fixed with methanol/acetone (1:1) for 10 min at 20°C 
and then permeabilized for 5min in 0.2% Triton-X100 in 
PBS. After a brief rinse non-specific sites were blocked 
with BSA 5%, NGS 3% in PBS for 1h. The following 
antibodies were used for an overnight incubation: anti-
ERβ (CWK-F12, 1:250, monoclonal), anti-Nup153 ([H-
161], Santa Cruz #sc-292438, 1:100, polyclonal). The 
following day, FITC and TRITC secondary anti-mouse 
and anti-rabbit antibodies (1:500, Jackson Immunological 
Research) were incubated for 1h. After washes nuclei were 
stained with DAPI.
Samples were analyzed with a confocal laser 
scanning system (TCS-SP2; Leica Microsystems and/or 
Nikon-Ti Eclipse equipped with a 20x-40x objective). Co-
localization of the two proteins was performed analyzing 
z-stacked images. Confocal settings were the same for 
all examined samples in order to compare fluorescence 
intensities.
Western-blot assay and co-immunoprecipitation
Protein extracts were obtained as in [2, 12, 40]. 
Specifically, samples were lysed in buffer containing 
50mM Tris-HCl (pH 7.4), 250 mM NaCl, 0.1% 
tritonX100, 5mM EDTA, 0.3% Empigen BB and 
supplemented with 1mM PMSF and protease inhibitor 
mix. Western Blot assay was performed using 40 μg of 
total extract. Co-immunoprecipitation experiments were 
performed using 4 μg of antibody for a range of 500-
700 μg of protein extract. Ademtech’s Bio-Adembeads 
paramagnetic bead system was used to immunoprecipitate 
the specific proteins. A negative control was performed 
with the same amount of protein extract sample 
immunoprecipitated with the corresponding purified IgG 
(Santa Cruz). Total proteins were resolved by SDS-PAGE 
using a 3-8% gradient and/or 10% Invitrogen Precast gel 
(NuPage, TA or MES buffer). Specific protein signals were 
revealed with ECL Prime (Amersham, GE Healthcare) and 
detected by UVIDOC (Eppendorf S.r.l.). The intensity of 
each band was evaluated by using UVIDOC and/or the 
NIH Image J 1.8 software (National Institutes of Health, 
Bethesda, Maryland, USA). Optical density values of 
specific proteins were normalized to that of tubulin, H1, 
HSP90 or fibrillarin.
RNA interference and transfection
Small interference to Nup153 was obtained with 60nM 
Trilencer-27mer siRNA duplexes as oligos mix (Origene, 
Rockville, MD, USA) transfected by Lipofectamine 
RNAiMAX according to the manufacturer’s instructions 
in hormone-deprived serum and after 48h treated with 
17β-estradiol (E2). Overexpression of ERβ was obtained 
with Expression vectors encoding the human ERβ full-length 
(530aa) or short isoform (485aa) as described [13].
RNA extraction and qRT analysis
RNA isolation, cDNA preparation and RNA 
quantification were performed as described [12, 13]. 
Briefly, real-time PCR (qRT-PCR) was repeated three 
times in duplicate on an ABI Prism 7500 Detection System 
and/or QuantStudio 5 Real-Time PCR System (Applied 
Biosystems). Aldolase and Gapdh served as endogenous 
controls.
Primers sequences, used with SYBR Green Master 
Mix (Applied Biosystems), were as described in [13] and 
as follow:
hNUP153:
5’-TGATAACATCTCAACTACCAGTGGTTT-3’ 
and 5’-GAGAGTGAGTGAGAACGTTCAGCTT-3’.
Chromatin immunoprecipitation
Chromatin cross-linking and immunoprecipitation 
(ChIP) assays were performed as described [13], using 
antibodies specific to eNOS (4μg; Type III, BD), ERβ 
(4μg; L-20, Santa Cruz) and ERβ (3μg, CWK-F12, 
DSHB). Negative controls were generated omitting 
antibody (NoAb). DNA fragments were recovered and 
analyzed by qRT-PCR as previously described [12]. 
Briefly, qRT-PCR were performed in duplicate or triplicate 
and the data, normalized to the corresponding DNA input 
control, were represented as Fold Induction +/-E2 or as 
Relative enrichment A.U. (Supplementary Figure 1).
Primers sequences for promoters, designed using 
Primer express 3.1 (Applied Biosystems), are as follows:
hNUP153 prom-eNOSpeak
5’-ACAATTTAACAACATCAACCATGTGA-3’ 
and 5’-CAAAAGTGTAGCAAAAGGATCTGATAA-3’.
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Statistical analysis
Data are expressed as mean ± SEM or as fold of 
induction as indicated in figures legend. Significance 
was calculated using a two-tailed t-test and/or one-way 
Analysis of Variance (ANOVA). P values of <0.05 were 
considered as significant in all tests.
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